Liposome based drug delivery as a potential treatment option for Alzheimer’s disease
Alzheimer’s disease is a neurodegenerative condition leading to atrophy of the brain and robbing nearly 5.8 million individuals in the United States age 65 and older of their cognitive functions. Alzheimer’s disease is associated with dementia and a progressive decline in memory, thinking, and socia...
Guardado en:
Autores principales: | Carely Hernandez, Surabhi Shukla |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wolters Kluwer Medknow Publications
2022
|
Materias: | |
Acceso en línea: | https://doaj.org/article/816dac8721d541b5954245e9e47ce1ce |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases
por: Claudia Riccardi, et al.
Publicado: (2021) -
In vivo Glioblastoma Therapy Using Targeted Liposomal Cisplatin
por: Ashrafzadeh MS, et al.
Publicado: (2020) -
Editorial: Organization and Functional Properties of the Blood-Brain Barrier
por: Darryl R. Peterson, et al.
Publicado: (2021) -
Wheat germ agglutinin-conjugated liposomes incorporated with cardiolipin to improve neuronal survival in Alzheimer’s disease treatment
por: Kuo YC, et al.
Publicado: (2017) -
Extensive frontal focused ultrasound mediated blood–brain barrier opening for the treatment of Alzheimer’s disease: a proof-of-concept study
por: So Hee Park, et al.
Publicado: (2021)